UroAlerts - Prostate Cancer Weekly

December 03, 2024

Videos

Peer-to-Peer Clinical Conversations

Prostate Cancer QuickTakes ESMO 2024 - ARANOTE, PEACE-3, and SPLASH Trials - Oliver Sartor

Oliver Sartor

Zachary Klaassen interviews Oliver Sartor about three significant prostate cancer trials presented at ESMO 2024.

INSPIRE Trial Investigates Immunotherapy for Molecularly Selected Advanced Prostate Cancer - Niven Mehra

Niven Mehra

Neeraj Agarwal interviews Niven Mehra about the INSPIRE trial.

Beyond the Abstracts

Adult Prostate Sarcoma: Demographics, Treatment Patterns, and Survival - Beyond the Abstract

Testosterone Therapy in Men after Radical Prostatectomy for Organ-Confined, Low-Intermediate Prostate Cancer - Beyond the Abstract

Conference Coverage

ESMO 2024: Prostate Cancer Efficacy Results from a Randomized Phase 3 Evaluation of Transdermal Estradiol Versus LHRH Agonists for Androgen Suppression in M0 Prostate Cancer

ESMO 2024: CC-94676-PCA-001: Clinical Activity of BMS-986365, a Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, in Heavily Pretreated Patients with mCRPC

ESMO 2024: Invited Discussant: CONTACT-02 Study and STAMPEDE Docetaxel Trials

Physician-Scientist Review Articles

Radium-223 in 2024 and Beyond: Resurrected and Disrupting the First-Line mCRPC Treatment Landscape

Articles

Editor Selected Abstracts and Commentaries

Prostate Cancer

Adipose Tissues Have Been Overlooked as Players in Prostate Cancer Progression.

Preoperative Briganti Nomogram Score and Risk of Prostate Cancer Progression After Robotic Surgery Beyond EAU Risk Categories.

Hugo™ Versus daVinci™ Robot-Assisted Radical Prostatectomy: 1-Year Propensity Score-Matched Comparison of Functional and Oncological Outcomes.

Impact of TP53 Loss-of-Function Alterations on the Response to PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients - Beyond the Abstract

Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies.

Active surveillance follow-up for prostate cancer: from guidelines to real-world clinical practice.

Systematic literature review and meta-analysis of health state utility values in metastatic castration-resistant prostate cancer.

Cross-shaped windows transformer with self-supervised pretraining for clinically significant prostate cancer detection in bi-parametric MRI.

Multimodal approach to optimize biopsy decision-making for PI-RADS 3 lesions on multiparametric MRI.

Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.

Prostate Image Quality System (PI-QUAL) Version 2 - A Practical Guide.

Clinical characteristics and treatment of patients with small cell prostate cancer: analysis of a real-world cohort from an oncology database.

Germline sequence variation in cancer genes in Rwandan breast and prostate cancer cases.

The role of Cabazitaxel in Patients With Castration-Resistant and Osseous Metastases Prostate Cancer. A Hellenic Cooperative Oncology Group Phase II Study: Cabazitaxel in mCRPC patients with osseous metastases.

Role of Chemokines and Cytokines in Prostate Cancer Skeletal Metastasis.

Feasibility, Tolerability, and Preliminary Clinical Response of Fractionated Radiopharmaceutical Therapy with 213Bi-FAPI-46: Pilot Experience in Patients with End-Stage, Progressive Metastatic Tumors.

ASCL1 regulates and cooperates with FOXA2 to drive terminal neuroendocrine phenotype in prostate cancer.

Cell-autonomous IL6ST activation suppresses prostate cancer development via STAT3/ARF/p53-driven senescence and confers an immune-active tumor microenvironment.

Gene-based burden tests of rare germline variants identify six cancer susceptibility genes.

Dietary pro-oxidant therapy by a vitamin K precursor targets PI 3-kinase VPS34 function.

Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibition.

Extracapsular extension risk assessment using an artificial intelligence prostate cancer mapping algorithm.

Targeting IRE1α reprograms the tumor microenvironment and enhances anti-tumor immunity in prostate cancer.

Functional inversion of circadian regulator REV-ERBα leads to tumorigenic gene reprogramming.

Nutritional Supplement with Fermented Soy in Patients Under Active Surveillance for Low-Risk or Intermediate-Risk Prostate Cancer: Results from the PRAEMUNE Trial.

Phenotypic evaluation of deep learning models for classifying germline variant pathogenicity.

Altered expression of vesicular trafficking machinery in prostate cancer affects lysosomal dynamics and provides insight into the underlying biology and disease progression.

Iron-loaded cancer-associated fibroblasts induce immunosuppression in prostate cancer.

Evaluation of ChatGPT as a Reliable Source of Medical Information on Prostate Cancer for Patients: Global Comparative Survey of Medical Oncologists and Urologists.

Validation of an artificial intelligence-based prognostic biomarker in patients with oligometastatic Castration-Sensitive prostate cancer.

Unmasking Neuroendocrine Prostate Cancer with a Machine Learning-Driven Seven-Gene Stemness Signature That Predicts Progression.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2024 Digital Science Press, LLC